NAGA’s Shareholders Approve the Merger With CAPEX.com With a Positive Vote of 99.81%
22.4.2024 10:13:00 CEST | Business Wire | Press Release
The NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the All-in-One Financial Super-App NAGA, is pleased to announce that the Extraordinary General Meeting of the Shareholders which took place on April 12th has given the green light for the merger with CAPEX.com with a vote of 99.81%.
During the EGM, the newly appointed CEO of NAGA AG, Octavian Patrascu, put forward the vision for the “New NAGA”, which boasts a new regulatory framework of 9 licenses (with 2 additional in the process of approval) and 12 offices worldwide, increasing the global reach of the Group and ability to service over 100 countries. Vouching to sustain the company’s mission to democratize access to financial markets, Patrascu presented the roadmap for the company’s product and the expected seamless integration of all 4 financial verticals into a unified ecosystem for the user, the NAGA SuperApp.
Key highlights from his presentation include:
- Market Expansion: Detailed plans to propel NAGA into new and untapped markets, broadening the company's global footprint and harnessing new customer segments. This move is expected to significantly boost the company's market share and strengthen its position in the competitive financial technology landscape.
- Product and App Enhancements: Recognizing the pivotal role of technology in financial services, he announced major upgrades to the NAGA app, focusing on improving user experience. The product development roadmap includes improving the community-based ecosystem, AI integrations and unique features empowering the users to become creators of their own financial instruments.
- NAGA SuperApp: Introduced plans to unify all existing NAGA services into a single, integrated platform – the NAGA SuperApp, creating a unified ecosystem, offering users a complete range of services ranging from trading and investing to crypto, neo-banking and personal finance management.
- Merger with CAPEX.com: Pending regulatory approval and the entry of the general meeting resolutions in the commercial register, the strategic merger is designed to boost NAGA’s financial efficiency, capitalizing on the synergies between the two companies (internal evaluation shows that these can exceed $10 million per year). NAGA will additionally benefit from Capex’s skilled management which has a proven track record, with a core team that has been working beside Octavian Patrascu for over 15 years. Additionally, joint strategies are expected to improve marketing efficiency, reducing client acquisition costs, and boosting brand reach and recognition.
Octavian Patrascu commented on the strong confidence vote: “This EGM was a first for me as the CEO of NAGA Group and I'm excited that it resulted in the approval of the merger and the new proposed Supervisory Board, with such a significant voting majority. Securing this vote will allow us, after the regulatory approvals for the merger, to execute the new business plan. We are expanding the global reach of NAGA and upgrading the SuperApp to offer a true all-in-one user experience, unique in the world of Fintech.”
After the merger approval, Patrascu is positioned to become NAGA's majority shareholder, with a personal financial investment in the deal. He brings to NAGA over 15 years of experience in founding and leading companies to achieve global prominence.
Being the Founder and CEO of CAPEX.com, he orchestrated its expansion to a global presence with six licenses, turning it into a multinational powerhouse with hundreds of employees and offices across four continents. With 3 major exits from high-profile ventures such as Trade.com, Markets.com, and Vector Watch, his track record demonstrates a consistent ability to identify growth opportunities, navigate complex market dynamics, and deliver exceptional outcomes.
The “New NAGA” is set to benefit from an expanded userbase of over 1.6 million registered users to date and a roadmap to achieve over 5 million registered users by 2025/26. Leveraging NAGA’s technological ecosystem on the existing clients of Capex and respectively using Capex’s international operational and licensing infrastructure to optimize NAGA’s client base will drive an improved Client lifetime value and overall profitability. After the merger, NAGA will be able to draw from the broader talent pool and local presence offered by the 9 local CAPEX offices.
About NAGA
NAGA is a leading German Fintech Company offering a SuperApp with the aim to merge social trading, investing in stocks, crypto, and neo banking into one unified platform, powered by its proprietary advanced technology. Operating in over 100 countries with 9 local offices, NAGA offers a diverse range of services for both fiat and cryptocurrencies. The platform features a physical VISA card with fiat and automatic crypto conversion plus cashback, dynamic social feeds, and advanced autocopy functions, enabling users to replicate the strategies of successful traders. Designed for a global community, NAGA provides an inclusive and efficient financial ecosystem for personal finance and trading.
Language: | English | |
Company: | The NAGA Group AG Hohe Bleichen 12 20354 Hamburg Germany | |
E-mail: | ||
Internet: | ||
ISIN: | DE000A161NR7 | |
WKN: | A161NR | |
Indices: | Scale 30 | |
Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Munich, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422873077/en/
Contact information
Andreas Luecke
The NAGA Group AG
press@naga.com
www.naga.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom